Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects (Q37792340)

23 August 2017

title

Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects (English)

1 reference

23 August 2017

Kazuo Maruyama

1 reference

23 August 2017

language of work or name

English

0 references

publication date

28 October 2010

1 reference

full work available at URL

23 August 2017

https://api.elsevier.com/content/article/PII:S0169409X1000181X?httpAccept=text/xml

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

https://api.elsevier.com/content/article/PII:S0169409X1000181X?httpAccept=text/plain

20 July 2024

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Advanced Drug Delivery Reviews

20 July 2024

published in

1 reference

23 August 2017

1 reference

23 August 2017

1 reference

23 August 2017

page(s)

161-169

1 reference

Pharmacokinetics of stealth versus conventional liposomes: effect of dose

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Cardiac safety of liposomal anthracyclines

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

The reticuloendothelial system and bloodstream clearance

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Liposomal doxorubicin-induced toxicity: depletion and impairment of phagocytic activity of liver macrophages

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol)

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Transport of molecules across tumor vasculature

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo.

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Liposomes for the sustained drug release in vivo

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol)

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol).

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Some negatively charged phospholipid derivatives prolong the liposome circulation in vivo

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Effects of mixed polyethyleneglycol modification on fixed aqueous layer thickness and antitumor activity of doxorubicin containing liposome

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Opsonophagocytosis of liposomes by peritoneal macrophages and bone marrow reticuloendothelial cells

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Direct measurement of the extravasation of polyethyleneglycol-coated liposomes into solid tumor tissue by in vivo fluorescence microscopy

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Future directions of liposome- and immunoliposome-based cancer therapeutics

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Liposomal encapsulated anti-cancer drugs

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Cardiac safety of liposomal anthracyclines

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Pros and cons of the liposome platform in cancer drug targeting

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Liposomal drug formulations. Rationale for development and what we can expect for the future

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Possibility of active targeting to tumor tissues with liposomes

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Uptake and processing of immunoglobulin-coated liposomes by subpopulations of rat liver macrophages

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Characterization of in vivo immunoliposome targeting to pulmonary endothelium

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Improvement of therapeutic effect by using Fab' fragment in the treatment of carcinoembryonic antigen-positive human solid tumors with adriamycin-entrapped immunoliposomes.

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Immunoliposomes bearing polyethyleneglycol‐coupled Fab′ fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

The transferrin receptor: its diagnostic value and its potential as therapeutic target

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Transferrin receptor in oral tumors

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Intracellular targeting of sodium mercaptoundecahydrododecaborate (BSH) to solid tumors by transferrin-PEG liposomes, for boron neutron-capture therapy (BNCT).

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Boron neutron capture therapy for cancer. Realities and prospects.

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers.

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

Passive and active drug targeting: drug delivery to tumors as an example

20 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.ADDR.2010.09.003

20 July 2024

Identifiers

DOI

1 reference

23 August 2017

1 reference